robatumumab

Robatumumab is a fully human monoclonal antibody of the IgG1/kappa isotype that targets the insulin-like growth factor 1 receptor (IGF-1R), also known as CD221. By binding to membrane-bound IGF-1R with high affinity and selectivity, robatumumab blocks the interaction of IGF-1 with its receptor and inhibits downstream signaling pathways such as PI3K/Akt. This leads to downregulation of survival signals in tumor cells, induction of apoptosis, and decreased cellular proliferation. Robatumumab was developed primarily for oncology indications including osteosarcoma, Ewing sarcoma, sarcoma, colorectal cancer, and other solid tumors. The drug was originally developed by Schering-Plough and later by Merck following acquisition[3][4][5][7].

Other names

robatumumab